Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024 [Yahoo! Finance]
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health, Inc. (NASDAQ: JAGX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.